Article
Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal
Building Winning Oncology Teams That Last
Clips
Summary
In this episode of the Oncology Voice Network, Dr. Kirk Shepard sits down with Spencer Weneck and Christian Camp to break down what truly makes an oncology organization resilient, competitive, and future-ready.
How do leading pharma and biotech teams keep up with oncology’s relentless pace? In this episode of the Oncology Voice Network, Dr. Kirk Shepard sits down with Spencer Weneck and Christian Camp to break down what truly makes an oncology organization resilient, competitive, and future-ready. Hear firsthand insights into today’s most urgent challenges: navigating the shift from an employer to a candidate-driven market, adapting to patent cliffs and M&A waves, and outsmarting the industry’s unparalleled war for talent. Discover why talent development, cultural fit, and cross-functional leadership are make-or-break factors—and why so many companies lose their way by ignoring them. Get inspired by real-life examples, honest lessons from failure, and a deep dive into how shared learning environments like OVN are resetting industry standards. Listen now and future-proof your oncology team.
Related Topics
You May Also Like
Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal
Article
Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer
Value assessment of oncology drugs using a weighted criterion-based approach
Article
Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD
Outcome measures for oncology alternative payment models: practical considerations and recommendations
Article
Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
Article
M. Bertagnolli and J. Tabernero
Value assessment frameworks in oncology: championing concordance through shared standards
Article
E.M. Ray, L.A. Carey, K.E. Reeder-Hayes